HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G Considering “Value-Driven” Consumer Health Opportunities

This article was originally published in The Tan Sheet

Executive Summary

Procter & Gamble says consumer health is “a space that we like” for mergers and acquisitions or organic growth, even though sales for the firm’s health care segment slumped 2% in its latest quarter. A financial analyst expects news this year on who will succeed CEO A.G. Lafley.

You may also be interested in...



Lafley Back At P&G Helm As McDonald’s Tenure Ends At Four Years

Procter & Gamble turns to its former leader, previously replaced by Bob McDonald in 2009, after facing investor and analyst pressure to shake up management. Lafley’s return as CEO “provides us with new hope,” one market analyst says.

Procter & Gamble Opens New Chapter With Supplement Deal

Procter & Gamble buys Vermont-based whole foods supplement maker New Chapter Organics, expanding its consumer business and gaining a foothold in the natural products space. P&G intends to keep New Chapter a wholly owned subsidiary and leave most of its operations intact.

P&G Restores Volume Growth In Beauty, Grooming After Pricing Run

Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS139767

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel